Abstract: Biochemical scaffolds for regulating mammalian cell function. The biochemical scaffolds include a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and/or neurotransmitter modulator. The vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to harmonic oscillation for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by the liquid medium, and, when the biochemical scaffolds are delivered to and, thus, in communication with biological tissue, the biochemical scaffolds induce specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof.
Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
Abstract: Compositions and methods of using and manufacturing an oral pharmaceutical anhydrous suspension are provided. The anhydrous suspension is suitable to suspend active pharmaceutical ingredients (APIs), improve the stability of oral pharmaceutical suspensions, and help in the formation of a thermo-reversible gel and shear thinning to keep the APIs suspended. The anhydrous suspension disclosed herein may include glyceryl distearate NF (e.g., in an amount of from about 0.1 wt. % to about 10 wt. %) and stearoyl polyoxyl-32 glycerides NF (e.g., in an amount of from about 0.1 wt. % to about 10 wt. %). In embodiments, the anhydrous suspension also includes glycerin (e.g., in an amount of about 5 wt. %). The anhydrous suspension may also include one or more of medium chain triglycerides NF, vitamin E acetate (DL) USP liquid (1 IU/mg), flavoring agent (e.g., a sweeter or other flavoring agent), ascorbyl palmitate NF, and other components.
Abstract: The disclosure relates to methods of improving safety, efficacy, or both, of pharmaceutically active aminothiol compounds by delivering them in a thiol-protected form and, preferably intracellularly.
Abstract: Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.
Type:
Application
Filed:
September 19, 2023
Publication date:
April 25, 2024
Inventors:
Kallanthottathil G. Rajeev, Souvik Biswas, Padma Malyala, Lisa N. Kasiewicz, Alexandra Chadwick, Caroline Reiss
Abstract: Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation. The disclosure also provides pharmaceutically acceptable compositions comprising compounds and methods for the treatment of EGFR mutant-related cancers.
Type:
Application
Filed:
October 30, 2023
Publication date:
April 25, 2024
Applicant:
BeiGene Switzerland GmbH
Inventors:
Bailin Lei, Huaqing Liu, Songzhe Han, Zhiwei Wang
Abstract: Anaphthalene ring-containing compound, a pharmaceutical composition containing same, and the use thereof. A naphthalene ring-containing compound as represented by formula III, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compound is new in structure and has a better activity on cancers.
Abstract: The invention provides a CLIPTAC comprising: (a) a first portion comprising a ligand for an intracellular target protein; (b) a second portion comprising a ligand for an E3 ubiquitin ligase; and (c) a linker portion covalently coupling the first and second portions; wherein the linker comprises a covalent bond produced by a bioorthogonal click reaction between a compatible pair of reactive moieties. CLIPTAC precursor compositions and CLIPTAC precursors are also provided, together with pharmaceutical compositions comprising the CLIPTAC, CLIPTAC precursor compositions and CLIPTAC precursors, and methods of treatment using the same.
Type:
Application
Filed:
September 5, 2023
Publication date:
April 25, 2024
Applicant:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Thomas Daniel HEIGHTMAN, Honorine LEBRAUD
Abstract: A formulation includes a plurality of polymers including a hydrophobic polymer backbone (for example, formed via radical polymerization), a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one cationic group, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one hydrophilic polymer, a first therapeutic compound, and a second therapeutic compound, wherein the second therapeutic compound is different from the first therapeutic compound and includes a nucleic acid.
Type:
Application
Filed:
December 14, 2023
Publication date:
April 25, 2024
Inventors:
Song Li, Jingjing Sun, Yichao Chen, Yixian Huang, Yanhua Liu, Binfeng Lu
Abstract: Disclosed are POEGMA-aptamer conjugates with a reduced or eliminated host-immune response. An example conjugate includes an aptamer conjugated to a POEGMA having a plurality of side chains, where each side chain includes 1 to 6 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of making the conjugate and methods of using the conjugate. An example method of use includes a method of controlling coagulation in a subject.
Type:
Application
Filed:
February 22, 2022
Publication date:
April 25, 2024
Inventors:
Ashutosh Chilkoti, Bruce Sullenger, Imran Ozer, Angus Hucknall, Juliana Layzer, George Pitoc
Abstract: The present disclosure relates to methods of reducing accelerated blood clearance of at least one pegylated therapeutic composition in a subject suffering from a disease and in need of treatment. The methods involve administering at least one high molecular weight polyethylene glycol composition to a subject suffering from a disease. The administration of at least one high molecular weight polyethylene glycol composition can also be used to increase the circulation half-life of at least one pegylated therapeutic composition as well as restore the pharmacokinetics of the pegylated therapeutic composition in a subject having a high titer of anti-polyethylene glycol antibodies.
Abstract: Transcription factors (TFs) represent a major class of therapeutic targets for the treatment of human diseases including cancer. Although the biological function and even crystal structure of many TFs have been clearly elucidated, there is still no viable approach to target the majority of TFs, thus rendering them undruggable for decades. PROTACs (PROteolysis TArgeting Chimeras) have emerged as a powerful tool for the pharmaceutical development since the effect of PROTACs largely relies on engineered protein-protein interaction to aid the degradation of targets by the ubiquitin-proteasome system (UPS). The present disclosure provides a DNA-PROTAC platform for targeted degraders of individual TFs of interest. These DNA based Transcription Factor targetting PROTACS (or “TF-PROTACS”) may provide specificity to TF degradation based on the conserved DNA-binding motifs of respective TFs.
Type:
Application
Filed:
November 27, 2023
Publication date:
April 25, 2024
Applicants:
Beth Israel Deaconess Medical Center, Inc., Icahn School of Medicine at Mount Sinai
Abstract: A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (TFRC) and/or receptor for advanced glycation end products (RAGE). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system.
Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
Type:
Application
Filed:
February 9, 2023
Publication date:
April 25, 2024
Inventors:
Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
Abstract: The present disclosure provides a method to translocate a molecule across cellular membrane by using a transferrin-binding protein. The transferrin-binding protein is capable of specifically binding to transferrin and not disturbing the interaction between transferrin and transferrin receptor.
Abstract: The present disclosure relates to a novel antibody-drug conjugate (ADC) targeting claudin 18 isoform 2 (CLDN18.2), an active metabolite of the ADC, a method of producing the ADC, use of the ADC for the treatment and/or prevention of diseases, and use of the ADC for producing a drug for the treatment and/or prevention of diseases, more specifically hyperproliferative and/or angiogenic diseases, for example, cancer, and more particularly, to an antibody-drug conjugate including a novel antibody or antigen-binding fragment thereof that binds to CLDN18.2, and a pharmaceutical composition including the same.
Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
Type:
Application
Filed:
October 11, 2023
Publication date:
April 25, 2024
Inventors:
Christoffer NIELSEN, Niels BEHRENDT, Lars Henning ENGELHOLM
Abstract: Drug conjugates having formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, (I) wherein D is covalently attached via a hydroxy or amine group to (X)b if any, or (AA)w if any, or to (T)g if any, or (L); that are useful in the treatment of cancer.
Type:
Application
Filed:
April 21, 2021
Publication date:
April 25, 2024
Inventors:
Alfonso LATORRE LOZANO, Valentín MARTÍNEZ BARRASA, Andrés M. FRANCESCH SOLLOSO, María Del Carmen CUEVAS MARCHANTE
Abstract: The present invention relates to compositions comprising a delivery vehicle conjugated to a targeting domain, wherein the delivery vehicle comprises at least one agent, and wherein the targeting domain specifically binds to an endothelial marker. The invention also relates to methods of treating or preventing neurological or pulmonary conditions using the described compositions.
Type:
Application
Filed:
December 1, 2023
Publication date:
April 25, 2024
Inventors:
Vladimir Muzykantov, Drew Weissman, Hamideh Parhiz, Vladimir V. Shuvaev, Oscar Marcos-Contreras
Abstract: Ligand-bound gold clusters and compositions comprising the ligand-bound gold clusters are used for treating depression and manufacturing a medicament for treatment of depression. Methods for treating depression.
Abstract: Provided herein are certain compositions and methods for nanoparticle seed substrates for self-assimilable nanoparticles and methods for optimized design of the same.
Abstract: The present invention provides a non-viral polyplex particle for delivering nucleic acid to cells, comprising an effective amount of polyethylenimine complexed with an effective amount of the nucleic acid; and an effective amount of an anionic biomaterial that envelops the complexed acetylated polyethylenimine and nucleic acid.
Abstract: Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).
Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.
Type:
Application
Filed:
May 1, 2023
Publication date:
April 25, 2024
Inventors:
Joseph BURNS, Kathryn ELLIS, Adam PALERMO, Martin SCHWANDER, Jonathon WHITTON
Abstract: Provided herein are compositions, systems, and methods comprising effector proteins, effector partners, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and/or engineering of nucleic acids.
Type:
Application
Filed:
September 17, 2023
Publication date:
April 25, 2024
Inventors:
Timothy Robert ABBOTT, Aaron DELOUGHERY, David PAEZ-ESPINO, Benjamin Julius RAUCH
Abstract: Provided in the present disclosure include targeted therapeutics for regulating gene transcription at a specific locus (or loci). Such targeted therapeutics can be used as novel genomic therapeutics for treating and/or preventing a disease or disorder that is tightly associated with the locus where the gene transcription is reprogrammed using the present systems. The regulatory system comprises a macromolecular complex of transcription effector proteins that is directed to a locus using CRISPR-dCas9.
Type:
Application
Filed:
October 29, 2023
Publication date:
April 25, 2024
Inventors:
Thomas T. Tibbitts, Diego Borges-Rivera
Abstract: Described herein are variant adeno-associated virus (AAV) capsid polypeptides and gene therapeutics thereof for use in the treatment or prevention of hearing loss.
Type:
Application
Filed:
May 4, 2023
Publication date:
April 25, 2024
Inventors:
Steven Pennock, Adrian M. Timmers, Mark Shearman, Christopher Bartolome, Wang Xiaobo, Prahav Dinesh Mathur, Phillip M. Uribe, Stephanie Szobota, Bonnie E. Jacques, Alan C. Foster, Fabrice Piu
Abstract: The disclosure features compositions and methods for the treatment of inner ear dysfunction, such as hearing loss or vestibular dysfunction, that reduce inflammatory or cell-mediated immune toxicity in the inner ear, thereby improving transduction and therapeutic efficacy. The disclosure provides a variety of compositions that include a nucleic acid vector that contains a polynucleotide encoding a therapeutic agent operably linked to a ubiquitous promoter and inhibitor of inflammatory or immune cell signaling. The disclosed compositions and methods can be used to increase expression of the therapeutic agent in a subject, such as a human subject suffering from an inner ear dysfunction, while minimizing undesirable immune activation resulting from off-target expression of the target protein in immune cells of the inner ear.
Type:
Application
Filed:
February 22, 2022
Publication date:
April 25, 2024
Inventors:
Adam PALERMO, Ning PAN, Gabriela PREGERNIG, Jonathon WHITTON, Xichun ZHANG
Abstract: The invention features compositions and methods useful in treating inflammation of the gut, such as inflammation associated with inflammatory bowel disease, by modulating ?? T cells (e.g., V?4+ cells). Particular embodiments include V?4+ cells expressing heterologous protein; polynucleotides containing genes contributing to functional expression of BTNL3, BTNL8, and HNF4A; methods of treating a subject using V?4+ cells or gene therapy; and methods of identifying a subject having imitations associated with inflammation of the gut. Compositions and methods of the invention can be used in the treatment of inflammation and cancer of the gut.
Type:
Application
Filed:
August 11, 2023
Publication date:
April 25, 2024
Applicant:
KING'S COLLEGE LONDON
Inventors:
Adrian HAYDAY, Robin DART, Natalie PRESCOTT, Pierre VANTOUROUT, Iva ZLATAREVA
Abstract: Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatment of TREM2-associated diseases and disorders, especially neurological diseases such as Alzheimer's Disease (AD), Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) or Nasu-Hakola Disease (NHD).
Type:
Application
Filed:
October 2, 2023
Publication date:
April 25, 2024
Inventors:
Sitharthan Kamalakaran, Priyam Raut, Anindya Kumar Sen, Benjamin Michael Shykind, Jessica Ruth Willen, Neda Masoudi
Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
Abstract: The present disclosure provides compositions and methods for the treatment of ocular diseases associated with angiogenesis, particularly wet age-related macular degeneration.
Type:
Application
Filed:
October 5, 2023
Publication date:
April 25, 2024
Applicant:
4D MOLECULAR THERAPEUTICS INC.
Inventors:
Christian BURNS, Melissa CALTON, Meredith LEONG, Paul SZYMANSKI
Abstract: Embodiments herein describe systems and methods to enhance RNA stability and uses thereof. Many embodiments alter the sequence of an RNA therapeutic molecule (e.g., vaccines) to encode for a variant peptide while maintaining and/or increasing stability of the RNA therapeutic.
Type:
Application
Filed:
June 30, 2021
Publication date:
April 25, 2024
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Disclosed herein are compositions comprising one or more subgenomic Flavivirus RNA (sfRNA) elements and using those compositions in methods of improving mRNA transcript stability, improving mRNA transcript translation efficiency, enhancing gene therapy, and treating and/or preventing a disease or disorder.
Abstract: The present disclosure relates to ratiometric detection compositions comprising a reference dye and a sensor dye that are PEGylated dyes, and microneedles comprising said compositions. The present disclosure further relates to methods of ratiometric detection/measurement/monitoring of analytes in a subject using the ratiometric detection compositions of the present disclosure.
Abstract: The present invention relates to the field of optical imaging. More particularly, it relates to a class of monoalkylated cyanine dyes with red to near-infrared (650-900 nm) emission characterized by pH responsiveness and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them. The monoalkylated cyanine dyes have general formula (I) wherein R1 and R3 are independently selected from the group consisting of hydrogen, -SO3H, —COOH and —CONH—Y; and R2 and R4 are hydrogen, or both R1 together with R2 and R3 together with R4, respectively and with the atoms to which they are bonded, form two aryl rings, optionally substituted with from 1 to 4 -SO3H groups; R5 is an alkyl optionally substituted by a group selected from —SO3H, —COOH and —CONH2.
Type:
Application
Filed:
December 16, 2021
Publication date:
April 25, 2024
Inventors:
Roberta NAPOLITANO, Francesco BLASI, Fulvio FERRETTI, Nicolò DIALE, Federica BUONSANTI, Massimo VISIGALLI, Alessia ADAMO
Abstract: The present invention relates to reporter protein fusion antibodies, transgenic animals expressing the same, and methods of using the reporter protein fusion antibodies.
Abstract: Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.
Type:
Application
Filed:
February 5, 2023
Publication date:
April 25, 2024
Inventors:
Tambet TEESALU, Pablo SCODELLER, Erkki RUOSLAHTI
Abstract: A dispersion for an X-ray target in which gold nanoparticles and sodium alginate or a calcium phosphate-based bone reinforcing material are dispersed, in which the gold nanoparticles are in contact with the sodium alginate or the calcium phosphate-based bone reinforcing material.
Type:
Application
Filed:
February 25, 2022
Publication date:
April 25, 2024
Applicant:
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
Abstract: The present disclosure relates to the field of fibroblast activation protein (FAP) inhibitors, conjugates comprising the novel FAP inhibitors, including radiotracers, for the imaging, diagnosis and treatment of conditions characterized by overexpression of FAP.
Type:
Application
Filed:
September 25, 2023
Publication date:
April 25, 2024
Applicants:
Nuclidium AG, University of Basel
Inventors:
Leila JAAFAR-THIEL, Melpomeni FANI, Jacopo MILLUL, Francesco DE ROSE
Abstract: Disclosed herein is a fractionated dosing regimen of 131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer. The dosing regimen may include a single dosing cycle or multiple dosing cycles. The radiation therapy as described herein may be administered pursuant to a first dosing cycle and a second dosing cycle, with a delay between the two cycles necessitated by a medical reason of the subject.
Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (I-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.
Abstract: The present disclosure provides methods and related compositions that incorporate a molecularly targeted approach via the integrin subtype ?v?6 using Peptide Receptor Radionuclide Therapy (PRRT) and a theranostic approach.
Type:
Application
Filed:
December 3, 2021
Publication date:
April 25, 2024
Applicant:
The Regents of the University of California
Abstract: A nuclide-labeled inhibitory peptide, and a preparation method therefor and use thereof are provided. The nuclide-labeled inhibitory peptide is prepared by labeling ASF1a peptide with 68Ga/177Lu by DOTA, and an amino acid sequence of the ASF1a peptide is YGRKKRRQRRRCASTEEKWARLARRIAGAGGVTLDGFGGCA (as shown in SEQ ID NO: 1). The 68Ga labeled ASF1a inhibitory peptide of the present invention displays the expression level of ASF1a of a tumor through PET/CT imaging, has good imaging sensitivity, can specifically screen high-expression and low-expression individuals, and achieves noninvasive prediction of the efficacy of tumor immunotherapy. The 177Lu-labeled ASF1a inhibitory peptide provides a novel and effective therapeutic strategy for a tumor that highly expresses ASF1a and is not effective for immunotherapy.
Abstract: The present invention relates to a 215- to 222-nm wavelength laser light generating device comprising: an excitation light source part for converting a laser light with a wavelength of 1030 to 1064 nm to a second harmonic, and generating a laser light with a wavelength of 515 to 532 nm; an optical parametric oscillating part for generating a signal light with a wavelength of 858 to 887 nm and an idler light with a wavelength of 1288 to 1330 nm using the laser light with the wavelength of 515 to 532 nm as an excitation light; a separating part for separating the signal light and the idler light; a first wavelength converting part for generating a fourth harmonic from the signal light; a second wavelength converting part for generating a deep ultraviolet light with a wavelength of 215 to 222 nm by sum frequency with a second harmonic of the excitation light from the idler light; and a coupling part for coupling the fourth harmonic from the first wavelength converting part and the deep ultraviolet light from the
Abstract: The present invention relates to a 399.08-nm wavelength ultraviolet laser light generating device, comprising: an excitation light source part for converting a 1064.2-nm laser light to a second harmonic, and generating a 532.1-nm laser light; an optical parametric oscillating part for generating a 798.15-nm signal light and a 1596.3-nm idler light using the 532.1-nm laser light; a first wavelength converting part for generating a 399.08-nm light by sum frequency generation of the 1596.3 nm idler light and a 532.1-nm light; and a second wavelength converting part for generating a 399.08-nm light of a second harmonic from the 798.15-nm signal light. The order of the first wavelength converting part and the second wavelength converting part is random. The present invention relates to a 228.04-nm wavelength ultraviolet laser light generating device comprising the 399.08-nm wavelength laser light generating device and a third wavelength converting part for subjecting a 399.08-nm light and a 532.
Abstract: A method of sterilizing an Intracervical Insemination (ICI) fertility kit, for use in performing self-insemination. Each sterile kit comprises: one to three sets of individually wrapped sterile, disposable, syringes and optionally semen collection jars; printed instructions; and a QR code. The collection jar comprises a snap-on lid, and an inner surface with seamless edges to prevent semen residue. The syringes and optionally the jars are sealed in plastic wraps permeable to air and gas, and impermeable to pathogens; and are sterilized via gamma radiation or ethylene oxide. Fresh or frozen, unwashed or washed, semen is deposited into the jar, pulled into the syringe, and administered cervically during a user's maximum monthly level of luteinizing hormone. The syringe distal end is designed to push all semen out of the syringe then plug the end closed, while preventing semen residue from collecting within the syringe. Large circular syringe handles facilitate stable handling.